Trial Profile
A Study to Evaluate the Visual Outcome After 6-Year Follow-Up in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Treated With Intravitreal Bevacizumab or Ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 13 Jun 2016 New trial record